Clinical Course and Risk Factors of Lenvatinib-Related Hypothyroidism in Hepatocellular Carcinoma: A Retrospective Cohort Study.

ABSTRACT:

Background

Lenvatinib-related hypothyroidism occurs in 16%-22% of patients with hepatocellular carcinoma and may affect treatment management. Previous studies have reported elevated serum thyroid stimulating hormone (TSH) levels despite levothyroxine therapy, indicating the need for research on the optimal levothyroxine dose during lenvatinib therapy.

Aims

We aimed to explore the effect of lenvatinib on thyroid function, focusing on lenvatinib pharmacokinetics and factors influencing hypothyroidism development.

Methods and results

A retrospective cohort study involving 56 patients with hepatocellular carcinoma treated with lenvatinib was conducted at the Mie University Hospital. The primary outcome was grade ≥ 2 hypothyroidism. Demographic data, treatment details, and

SUBMITTER: Shiraishi C 

PROVIDER: S-EPMC12819047 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature